Short Gut Syndrome Clinical Trials

NCT ID: NCT06240065 Enrolling by invitation - Short Gut Syndrome Clinical Trials

Predicting Success With Fiber Food Introduction in Short Bowel Syndrome

Start date: April 19, 2024
Phase: N/A
Study type: Interventional

Short bowel syndrome (SBS) is a rare but challenging condition in which patients have insufficient bowel length to meet fluid, electrolyte, and nutrient requirements without parenteral support. The purpose of this study is to determine how well dietary fiber is tolerated in patients with short bowel syndrome compared to patients without short bowel syndrome based on assessment of gastrointestinal symptoms, and corresponding changes in microbiome composition and metabolomics.

NCT ID: NCT05432648 Recruiting - Short Gut Syndrome Clinical Trials

Fiber Food Introduction in Pediatric Short Bowel Syndrome

Start date: May 8, 2022
Phase: N/A
Study type: Interventional

Short bowel syndrome (SBS) is a rare but challenging condition in which patients have insufficient bowel length to meet fluid, electrolyte, and nutrient requirements without parenteral support. The purpose of this study is to determine how well dietary fiber is tolerated in patients with short bowel syndrome compared to patients without short bowel syndrome based on assessment of gastrointestinal symptoms, and corresponding changes in microbiome composition and metabolomics.

NCT ID: NCT04604275 Recruiting - Short Gut Syndrome Clinical Trials

Functional Sucrase Deficiency in Short Bowel Syndrome Patients With Intestinal Failure

Start date: February 2, 2022
Phase: Phase 2
Study type: Interventional

Short gut syndrome with intestinal failure patients may have decreased production of disaccharidases, like sucrase, an enzyme responsible for digesting sugar in foods. This can happen due to loss of bowel length from surgery or from loss of cellular function in the intestines due to use of parenteral nutrition intravenously. Therefore, patients with these conditions may not be able to digest sucrose (sugar) fully. Patients might experience abdominal distension/pain, vomiting and diarrhea when sugar is taken in orally or through the g-tube, which can limit patients' ability to increase oral or g-tube feeds in short gut syndrome patients with intestinal failure. In patients with short gut syndrome and intestinal failure, the administration of exogenous sucrase (enzyme) may improve sucrose (sugar) digestion and thus the ability to tolerate more oral or g-tube feeds.

NCT ID: NCT04522778 Active, not recruiting - Quality of Life Clinical Trials

Innovative Central Line Securement Device in the Pediatric Population

Start date: November 5, 2020
Phase: N/A
Study type: Interventional

This study involves evaluating pediatric patients with central lines to determine differences in line complications and quality of life in those with a novel central line securement device (wrap) as compared to those who use a traditional securement device (dressing).

NCT ID: NCT02246816 Withdrawn - Clinical trials for Short Bowel Syndrome

A Open Label Extension Study for Subjects That Complete Study MP-101-CL-001

Start date: February 2015
Phase: Phase 3
Study type: Interventional

MP-101 will be evaluated in this study to see if it is safe and tolerable.

NCT ID: NCT02242656 Withdrawn - Clinical trials for Short Bowel Syndrome

A Phase III Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Investigational Product MP-101 in Subjects With Short Bowel Syndrome Who Have Had an Inadequate Response to Anti-Diarrheals

Start date: December 2014
Phase: Phase 3
Study type: Interventional

MP-101 will be evaluated in this study to see if it is safe, tolerable, and can help people with Short Bowel Syndrome. This study will also find out if taking MP-101 can improve the symptoms of Short Bowel Syndrome and reduce the number of times subjects experience bowel movements.